Literature DB >> 19491698

Prevalence and characteristics of Epstein-Barr virus-associated gastric carcinomas in Tunisia.

Mounir Trimeche1, Feriel Ksiâa, Sonia Ziadi, Sarra Mestiri, Mohamed Hachana, Riadh Ben Gacem, Badreddine Sriha, Sadok Korbi.   

Abstract

OBJECTIVE: Epstein-Barr virus (EBV) has been linked to gastric carcinoma (GC) with worldwide geographical variations of prevalence ranging from 1 to 18% of cases. Investigations carried out in north Africa have shown that some EBV-associated types of cancers are common in this area. This study was taken to determine the prevalence of EBV-associated GC in Tunisia.
METHODS: Ninety-six nonselected GC cases (male/female ratio 1.7/1, mean age 60.9 years, range: 20-88 years) were evaluated for the presence of EBV by polymerase chain reaction as well as by in-situ hybridization for EBV-encoded small RNAs (EBERs) and immunohistochemistry for LMP-1 and EBNA-2 expression.
RESULTS: EBV was detected by polymerase chain reaction in 36% of cases, whereas EBERs were detected in the tumor cells in only four cases (4.1%). Immunohistochemistry for LMP-1 and EBNA-2 was negative in all cases. The mean age for patients harboring EBERs-positive GC was 55.7 years (range: 52-59 years). All EBERs-positive GC cases were males of advanced clinical stage (pT3-pT4). According to Lauren's classification, two cases were of diffuse histological type and two cases were of intestinal type. In three cases, the tumors have a proximal location and in the remaining case the tumor arises in the antrum. All EBV strains detected from EBV-associated GC were exclusively of type A and D, prototype F, and XhoI-maintained variant.
CONCLUSION: We conclude that the prevalence of EBV-associated GC in Tunisia is low (4.1%), suggesting that this virus is not an important etiological factor in GC arising in north African populations. The clinicopathological profile of EBV-associated GC in Tunisia did not differ markedly from that found elsewhere.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19491698     DOI: 10.1097/MEG.0b013e32831f1f53

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  6 in total

1.  Characteristics of epstein barr virus variants associated with gastric carcinoma in Southern Tunisia.

Authors:  Dorra BenAyed-Guerfali; Wajdi Ayadi; Imen Miladi-Abdennadher; Abdelmajid Khabir; Tahia Sellami-Boudawara; Ali Gargouri; Raja Mokdad-Gargouri
Journal:  Virol J       Date:  2011-11-03       Impact factor: 4.099

2.  Genome-wide analysis of Epstein-Barr virus (EBV) isolated from EBV-associated gastric carcinoma (EBVaGC).

Authors:  Ying Liu; Wenjun Yang; Yaqi Pan; Jiafu Ji; Zheming Lu; Yang Ke
Journal:  Oncotarget       Date:  2016-01-26

3.  Clinicopathological Significance of EBV-Infected Gastric Carcinomas: A Meta-Analysis.

Authors:  Jung-Soo Pyo; Nae-Yu Kim; Dong-Wook Kang
Journal:  Medicina (Kaunas)       Date:  2020-07-13       Impact factor: 2.430

4.  Detection of Epstein-Barr virus in gastric adenocarcinoma: qPCR and FISH comparison.

Authors:  Igor Brasil-Costa; Carolina Rosal Teixeira de Souza; Iran Barros Costa; Liann Filiphe Pereira Dos Santos; Luana César Ferraz Paixão; Alessandra Alves Polaro; Talita Antonia Furtado Monteiro; Rommel Mario Rodríguez Burbano
Journal:  Med Microbiol Immunol       Date:  2021-12-03       Impact factor: 3.402

5.  Epstein-Barr virus-associated gastric carcinoma in Brazil: comparison between in situ hybridization and polymerase chain reaction detection.

Authors:  Marcos Antonio Pereira de Lima; Márcia Valéria Pitombeira Ferreira; Marcos Aurélio Pessoa Barros; Maria Inês de Moura Campos Pardini; Adriana Camargo Ferrasi; Silvia Helena Barem Rabenhorst
Journal:  Braz J Microbiol       Date:  2012-06-01       Impact factor: 2.476

6.  Association between Epstein-Barr virus infection and gastric cancer: a systematic review and meta-analysis.

Authors:  Ahmad Tavakoli; Seyed Hamidreza Monavari; Farid Solaymani Mohammadi; Seyed Jalal Kiani; Saber Armat; Mohammad Farahmand
Journal:  BMC Cancer       Date:  2020-06-01       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.